Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.62 |
| ▸ | NNMT | P40261 | 4/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014525 | 1.00 | GRM5 (0.62) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL1680438 | 0.84 | GRM5 (0.64) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL21382644 | 0.75 | GRM5 (0.65) | GRM5ALOX5APFEN1 | |
| SCHEMBL10283350 | 0.72 | NNMT (0.53) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL13538508 | 0.72 | NNMT (0.53) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL828125 | 0.72 | NNMT (0.53) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL13154323 | 0.72 | NNMT (0.57) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL21573715 | 0.72 | NNMT (0.57) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL1723715 | 0.72 | NNMT (0.53) | GRM5NNMTASIC3PIK3C3ALOX5AP | |
| SCHEMBL13004722 | 0.72 | NNMT (0.53) | GRM5NNMTASIC3PIK3C3ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | GRM5 4685/4885NNMT 935/4885ASIC3 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.